Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | PI4KA | P42356 | 2/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27343180 | 0.91 | ADORA3 (0.49) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL11459664 | 0.90 | PI4KA (0.48) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL28246105 | 0.86 | ADORA3 (0.45) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL17545193 | 0.84 | EHMT1 (0.46) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL7613659 | 0.84 | PI4KA (0.43) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL5666883 | 0.84 | ADORA3 (0.43) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL481525 | 0.84 | ADORA3 (0.55) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL31062627 | 0.84 | ADORA3 (0.55) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| Water SCHEMBL27885621 | 0.83 | ADORA3 (0.54) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| SCHEMBL9317293 | 0.83 | PI4KA (0.42) | ADORA3ADORA2API4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-16 | — | — | US | disclosed |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3645561-B1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-03-04 | — | — | US | disclosed |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-12-31 | — | — | US | disclosed |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-06-22 | — | — | US | disclosed |
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-08-27 | — | — | US | disclosed |
| US-20170327549-A1 | Adenylation Enzyme Inhibitors | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2017-11-16 | — | — | US | disclosed |
| EP-3185879-A1 | ADENYLATION ENZYME INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032332-A1 | ADENYLATION ENZYME INHIBITORS | STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2016-03-03 | — | — | WO | disclosed |
| EP-2376647-B1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2379578-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | Sutro Biopharma, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| EP-2376647-A1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | Sutro Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010081111-A1 | MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM | SUTRO BIOPHARMA, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081110-A1 | DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD | SUTRO BIOPHARMA, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-1960518-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067559-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874686-B2 | Anthranilyl-adenosinemonosulfamate analogs and uses thereof | ATIC, SLC35B2, ADORA1 | ADORA3 6/4885ADORA2A 5/4885PI4KA 2340/4885 |
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CCRL2, CCR3, LY6K | ADORA3 119/4885ADORA2A 383/4885PI4KA 1274/4885 |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | HAVCR2, CD4, CCR1 | ADORA3 2519/4885ADORA2A 1309/4885PI4KA 1903/4885 |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | ADORA3 2151/4885ADORA2A 1239/4885PI4KA 1808/4885 |
| US-11708353-B2 | Inhibitors of prolyl-tRNA-synthetase | GARS1, AARS1, NSUN3 | ADORA3 3593/4885ADORA2A 3583/4885PI4KA 3019/4885 |
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | IL2RA, CCR3, CD4 | ADORA3 1034/4885ADORA2A 2083/4885PI4KA 1915/4885 |
| US-20230190797-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | ADORA3 2519/4885ADORA2A 1309/4885PI4KA 1903/4885 |
| US-20200268794-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY | HAVCR2, CD4, CCR1 | ADORA3 2519/4885ADORA2A 1309/4885PI4KA 1903/4885 |
| US-20170327549-A1 | Adenylation Enzyme Inhibitors | ADSL, APEH, AHCY | ADORA3 134/4885ADORA2A 216/4885PI4KA 2183/4885 |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | ADORA3 2151/4885ADORA2A 1239/4885PI4KA 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.